吉西他滨
胞苷脱氨酶
卡培他滨
胸苷磷酸化酶
二氢嘧啶脱氢酶
转染
胸苷酸合酶
体内
分子生物学
脱氧胞苷
脱氧胞苷激酶
细胞培养
体外
生物
癌症研究
化学
癌症
生物化学
氟尿嘧啶
酶
遗传学
结直肠癌
生物技术
作者
Tatsuo Morita,Atsushi Matsuzaki,Shinsuke Kurokawa,Akihiko Tokue
出处
期刊:Oncology
[Karger Publishers]
日期:2003-01-01
卷期号:65 (3): 267-274
被引量:31
摘要
OBJECTIVE: Cytidine deaminase (CDD) is involved in the metabolism of new pyrimidine analogues, capecitabine (N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) and gemcitabine (2',2'-difluorodeoxycytidine). The purpose of the present study was to directly examine the role of CDD in tumor cells themselves in mediating the sensitivity to capecitabine compared with gemcitabine. METHODS: The human bladder cancer cell line T24 was transfected with human CDD2 cDNA by the lipofectin method. RESULTS: Transfection of CDD2 cDNA did not change the levels of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase (TS) but increased the CDD activity significantly (p < 0.01). Forced expression of CDD made T24 sensitive to 5'-deoxy-5-fluorocytidine (5'DFCR) in vitro and capecitabine in vivo, but resistant to gemcitabine both in vitro and in vivo. Tetrahydrouridine, a specific CDD inhibitor, abrogated the changes in the in vitro sensitivity to 5'DFCR and gemcitabine by transfection of CDD2 cDNA. Transfection of CDD2 cDNA resulted in a significant increase in cellular 5-fluorouracil level (p < 0.01) and inhibition of TS activity (p < 0.01) after treatment with 5'DFCR in vitro. CONCLUSIONS: The present study clearly showed direct evidence for the contribution of CDD in tumor cells themselves to the sensitivities to capecitabine and gemcitabine.
科研通智能强力驱动
Strongly Powered by AbleSci AI